A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study.
David J. Pinato,David J. Pinato,Lorenza Scotti,Alessandra Gennari,Emeline Colomba-Blameble,Saoirse Dolly,Angela Loizidou,John D. Chester,Uma Mukherjee,Alberto Zambelli,Juan Aguilar-Company,Mark Bower,Myria Galazi,Ramon Salazar,Alexia Bertuzzi,Joan Brunet,Ricard Mesia,Ailsa Sita-Lumsden,Johann Colomba,Fanny Pommeret,Elia Seguí,Federica Biello,Daniele Generali,Salvatore Grisanti,Gianpiero Rizzo,Michela Libertini,Charlotte Moss,Joanne Evans,Beth Russell,Rachel Wuerstlein,Bruno Vincenzi,Rossella Bertulli,Diego Ottaviani,Raquel Liñan,Andrea Marrari,M. C. Carmona-Garcia,Christopher C T Sng,Carlo Tondini,Oriol Mirallas,Valeria Tovazzi,Vittoria Fotia,Claudia Andrea Cruz,Nadia Saoudi-Gonzalez,Eudald Felip,Ariadna Roqué Lloveras,Alvin J.X. Lee,Thomas Newsom-Davis,Rachel Sharkey,Chris Chung,David García-Illescas,Roxana Reyes,Yien N. Sophia Wong,Daniela Ferrante,Javier Marco-Hernández,Isabel Ruiz-Camps,Gianluca Gaidano,Andrea Patriarca,Anna Sureda,Clara Martinez-Vila,Ana Sanchez de Torre,Lorenza Rimassa,Lorenzo Chiudinelli,Michela Franchi,Marco Krengli,Armando Santoro,Aleix Prat,Josep Tabernero,Mieke Van Hemelrijck,Nikolaos Diamantis,Alessio Cortellini +69 more
TL;DR: In this article, the authors compared the national impact of coronavirus disease 2019 (COVID-19) on the risk of death in UK patients with cancer versus those in continental EU.
Journal ArticleDOI
KRAS mutation in lung metastases from colorectal cancer: prognostic implications.
Michele Ghidini,Nicola Personeni,Silvia Bozzarelli,M. Baretti,Gianluca Basso,Paolo Bianchi,Maria Chiara Tronconi,Tiziana Pressiani,Fabio Grizzi,Laura Giordano,Alberto Malesci,Marco Alloisio,Luigi Laghi,Armando Santoro,Lorenza Rimassa +14 more
TL;DR: KRAS mutation is a negative prognostic factor in mCRC patients undergoing LM and administration of adjuvant chemotherapy after lung metastasectomy (LM) significantly improved both PFS and OS.
Journal ArticleDOI
Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Patients with Locally Advanced or Metastatic, Non-squamous, Non-small Cell Lung Cancer (NSCLC)
J. von Pawel,G.V. Scagliotti,Silvia Novello,Rodryg Ramlau,Adolfo Favaretto,Fabrice Barlesi,Wallace Akerley,Sergey Orlov,Armando Santoro,Frances A. Shepherd,David R. Spigel,Vera Hirsh,Lecia V. Sequist,Dale Shuster,Hamim Zahir,Qiang Wang,Brian Schwartz,R. von Roemeling,Alan Sandler +18 more
TL;DR: Subpopulation n HR (95% CI) P Value Median PFS, months Response Rate Tivantinib Placebo Tivonavir Placebo ITT 1,048 0.74 (0.64-0.85) < .0001 3.6 1.7 1.9 10.3% 6.5% EGFR genotype Wildtype 937 0.72 ( 0.62
Journal ArticleDOI
Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study.
Alessandra Bearz,I. Garassino,Raffaele Cavina,Adolfo Favaretto,Massimo Boccalon,Renato Talamini,Massimiliano Berretta,Simon Spazzapan,Cecilia Simonelli,Armando Santoro,Umberto Tirelli +10 more
TL;DR: Improved efficacy and mild toxicity observed in this clinically relevant patient population confirms Pemetrexed as an interesting choice in second-line treatment of NSCLC.
Journal ArticleDOI
Irinotecan and raltitrexed: an active combination in advanced colorectal cancer
C. Carnaghi,Lorenza Rimassa,I. Garassino,Paolo Andrea Zucali,Giovanna Masci,M. Fallini,Emanuela Morenghi,Armando Santoro +7 more
TL;DR: Results achieved with irinotecan and raltitrexed show that this regimen is active, despite 'not-negligible' toxicity, and may represent a useful regimen for specific subgroups of colorectal cancer patients.